Standout Papers

Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With... 2003 2026 2010 2018 2.4k
  1. Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer (2003)
    Masahiro Fukuoka, Seiji Yano et al. Journal of Clinical Oncology
  2. Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1 (2004)
    Giuseppe Giaccone, Roy S. Herbst et al. Journal of Clinical Oncology
  3. Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2 (2004)
    Roy S. Herbst, Giuseppe Giaccone et al. Journal of Clinical Oncology
  4. Targeting the dynamic HSP90 complex in cancer (2010)
    Jane B. Trepel, Mehdi Mollapour et al. Nature reviews. Cancer
  5. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology (2013)
    Neal I. Lindeman, Philip T. Cagle et al. Journal of Thoracic Oncology
  6. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study (2010)
    Federico Cappuzzo, Tudor–Eliade Ciuleanu et al. The Lancet Oncology
  7. American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer (2009)
    Christopher G. Azzoli, Sherman Baker et al. Journal of Clinical Oncology
  8. Cell Death Independent of Caspases: A Review (2005)
    Linda E. Bröker, Frank A.E. Kruyt et al. Clinical Cancer Research
  9. Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015)
    Gregory A. Masters, Sarah Temin et al. Journal of Clinical Oncology
  10. Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials (2005)
    Daphne W. Bell, Thomas J. Lynch et al. Journal of Clinical Oncology
  11. Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2017)
    Nasser H. Hanna, David H. Johnson et al. Journal of Clinical Oncology
  12. Randomized Controlled Trial of Resection Versus Radiotherapy After Induction Chemotherapy in Stage IIIA-N2 Non-Small-Cell Lung Cancer (2007)
    Jan P. van Meerbeeck, G. Kramer et al. JNCI Journal of the National Cancer Institute
  13. American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non–Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy (2011)
    Vicki L. Keedy, Sarah Temin et al. Journal of Clinical Oncology
  14. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial (2013)
    Marina Chiara Garassino, Olga Martelli et al. The Lancet Oncology
  15. Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study (2018)
    Giuseppe Giaccone, Chul Kim et al. The Lancet Oncology

Immediate Impact

4 by Nobel laureates 13 from Science/Nature 213 standout
Sub-graph 1 of 15

Citing Papers

New promises and challenges in the treatment of advanced non-small-cell lung cancer
2024 Standout
Lung cancer
2021 Standout
37 intermediate papers

Works of Giuseppe Giaccone being referenced

IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC
2019
Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.
1997
and 35 more

Author Peers

Author Last Decade Papers Cites
Giuseppe Giaccone 24196 20441 16575 754 45.7k
Jaap Verweij 27869 21972 13557 619 54.4k
Yung‐Jue Bang 20426 16587 10595 602 36.1k
Bruce E. Johnson 29340 28871 20418 411 49.7k
John D. Hainsworth 21144 12105 9981 623 36.4k
Daniel D. Von Hoff 23213 6568 19391 816 43.9k
Frances A. Shepherd 30783 32265 11958 662 48.5k
Adi F. Gazdar 27996 18968 36023 641 69.7k
Elisabeth G.E. de Vries 23721 7229 14152 1.0k 46.9k
Ming‐Sound Tsao 14968 13475 16214 644 36.3k
William D. Travis 15522 31140 6841 536 51.0k

All Works

Loading papers...

Rankless by CCL
2026